These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 18082532)

  • 1. The Clinical Outcomes Utilizing Revascularizaton and Aggressive Drug Evaluation trial: a vindication of the power of medical therapy for the secondary prevention of coronary heart disease.
    Sheikh F; Blumenthal RS; Amsterdam E
    Am J Cardiol; 2007 Dec; 100(12):1808-9. PubMed ID: 18082532
    [No Abstract]   [Full Text] [Related]  

  • 2. Is there an ischemic threshold beyond which percutaneous coronary intervention is beneficial in the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) Trial?
    Bangalore S; Messerli FH
    Am J Cardiol; 2007 Nov; 100(9):1495. PubMed ID: 17950818
    [No Abstract]   [Full Text] [Related]  

  • 3. Optimal medical therapy with or without percutaneous coronary intervention in older patients with stable coronary disease: a pre-specified subset analysis of the COURAGE (Clinical Outcomes Utilizing Revascularization and Aggressive druG Evaluation) trial.
    Teo KK; Sedlis SP; Boden WE; O'Rourke RA; Maron DJ; Hartigan PM; Dada M; Gupta V; Spertus JA; Kostuk WJ; Berman DS; Shaw LJ; Chaitman BR; Mancini GB; Weintraub WS;
    J Am Coll Cardiol; 2009 Sep; 54(14):1303-8. PubMed ID: 19778673
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimal medical therapy with or without percutaneous coronary intervention to reduce ischemic burden: results from the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial nuclear substudy.
    Shaw LJ; Berman DS; Maron DJ; Mancini GB; Hayes SW; Hartigan PM; Weintraub WS; O'Rourke RA; Dada M; Spertus JA; Chaitman BR; Friedman J; Slomka P; Heller GV; Germano G; Gosselin G; Berger P; Kostuk WJ; Schwartz RG; Knudtson M; Veledar E; Bates ER; McCallister B; Teo KK; Boden WE;
    Circulation; 2008 Mar; 117(10):1283-91. PubMed ID: 18268144
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Secondary prevention in persons with ischemic heart disease. Drug treatment and revascularization].
    Spácil J
    Cas Lek Cesk; 1985 May; 124(21):659. PubMed ID: 3874691
    [No Abstract]   [Full Text] [Related]  

  • 6. Impact of an initial strategy of medical therapy without percutaneous coronary intervention in high-risk patients from the Clinical Outcomes Utilizing Revascularization and Aggressive DruG Evaluation (COURAGE) trial.
    Maron DJ; Spertus JA; Mancini GB; Hartigan PM; Sedlis SP; Bates ER; Kostuk WJ; Dada M; Berman DS; Shaw LJ; Chaitman BR; Teo KK; O'Rourke RA; Weintraub WS; Boden WE;
    Am J Cardiol; 2009 Oct; 104(8):1055-62. PubMed ID: 19801024
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Pharmacologic prevention of cardiovascular diseases. Summary and perspectives].
    Kübler W
    Z Kardiol; 1992; 81 Suppl 4():221-2. PubMed ID: 1290302
    [No Abstract]   [Full Text] [Related]  

  • 8. Predictors of treatment response for depression and inadequate social support--the ENRICHD randomized clinical trial.
    Cowan MJ; Freedland KE; Burg MM; Saab PG; Youngblood ME; Cornell CE; Powell LH; Czajkowski SM;
    Psychother Psychosom; 2008; 77(1):27-37. PubMed ID: 18087205
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Beneficial impact of Xuezhikang on cardiovascular events and mortality in elderly hypertensive patients with previous myocardial infarction from the China Coronary Secondary Prevention Study (CCSPS).
    Li JJ; Lu ZL; Kou WR; Chen Z; Wu YF; Yu XH; Zhao YC;
    J Clin Pharmacol; 2009 Aug; 49(8):947-56. PubMed ID: 19602720
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Drugs in secondary prevention of coronary artery disease].
    Friedensohn A; Schlesinger Z
    Harefuah; 1989 Jan; 116(1):56-60. PubMed ID: 2651237
    [No Abstract]   [Full Text] [Related]  

  • 11. [Stable coronary heart disease--lessons from the COURAGE Study. With intensive drug therapy on the success track].
    MMW Fortschr Med; 2008 Jun; 150(23):38-9. PubMed ID: 18575368
    [No Abstract]   [Full Text] [Related]  

  • 12. [Prevention, management and control--aspects in heart and coronary diseases].
    Hofvendahl S
    Katilolehti; 1979 Mar; 84(3):119-24. PubMed ID: 376923
    [No Abstract]   [Full Text] [Related]  

  • 13. [Protocols for the prevention and treatment of thromboembolic disease. (IV). Antithrombotic therapy in coronary disease. The Editorial Committee on Protocols].
    Rev Esp Cardiol; 1993 Dec; 46(12):784-8. PubMed ID: 8134688
    [No Abstract]   [Full Text] [Related]  

  • 14. Secondary prevention in myocardial infarction survivors.
    Ir Med J; 1981 Sep; 74(9):245-7. PubMed ID: 7287385
    [No Abstract]   [Full Text] [Related]  

  • 15. Impact of optimal medical therapy with or without percutaneous coronary intervention on long-term cardiovascular end points in patients with stable coronary artery disease (from the COURAGE Trial).
    Boden WE; O'Rourke RA; Teo KK; Maron DJ; Hartigan PM; Sedlis SP; Dada M; Labedi M; Spertus JA; Kostuk WJ; Berman DS; Shaw LJ; Chaitman BR; Mancini GB; Weintraub WS;
    Am J Cardiol; 2009 Jul; 104(1):1-4. PubMed ID: 19576311
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Letter by Joshi regarding article, "Optimal medical therapy with or without percutaneous coronary intervention to reduce ischemic burden: results from the clinical outcomes utilizing revascularization and aggressive drug evaluation (COURAGE) trial nuclear substudy".
    Joshi SB
    Circulation; 2008 Dec; 118(25):e838; author reply e840-1. PubMed ID: 19106385
    [No Abstract]   [Full Text] [Related]  

  • 17. [Secondary prevention of ischemic cardiopathy. Current problems and outlook].
    Gherasim L
    Rev Med Interna Neurol Psihiatr Neurochir Dermatovenerol Med Interna; 1988; 40(4):289-300. PubMed ID: 2905511
    [No Abstract]   [Full Text] [Related]  

  • 18. [Current problems in prevention of ischemic heart disease and acute myocardial infarction].
    Trandafir V
    Viata Med Rev Inf Prof Stiint Cadrelor Medii Sanit; 1982 Sep; 30(9):193-7. PubMed ID: 6818756
    [No Abstract]   [Full Text] [Related]  

  • 19. Letter by Tarantini et al regarding article, "Optimal medical therapy with or without percutaneous coronary intervention to reduce ischemic burden: results from the clinical outcomes utilizing revascularization and aggressive drug evaluation (COURAGE) trial nuclear substudy".
    Tarantini G; Razzolini R; Iliceto S
    Circulation; 2008 Dec; 118(25):e839; author reply e840-1. PubMed ID: 19106386
    [No Abstract]   [Full Text] [Related]  

  • 20. Pharmacoinvasive management of acute coronary syndrome: incorporating the 2007 ACC/AHA guidelines: the CATH (cardiac catheterization and antithrombotic therapy in the hospital) Clinical Consensus Panel Report--III.
    Cohen M; Diez JE; Levine GN; Ferguson JJ; Morrow DA; Rao SV; Zidar JP; ;
    J Invasive Cardiol; 2007 Dec; 19(12):525-38; quiz 539-40. PubMed ID: 18180524
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.